Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RINGQUEST: Sacituzumab Tirumotecan in Understudied Genitourinary Tumors
NCT07716917Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in Papillary Renal Cell Carcinoma (PRCC), Urothelial Carcinoma With Variant Histology (UC-VH). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
Papillary Renal Cell Carcinoma (PRCC)Urothelial Carcinoma With Variant Histology (UC-VH)
Beyond the preview
Go deeper on NCT07716917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07716917.